SLAS
SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives.
SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives.
We are sponsors at this event!
Come and visit our team at our booth 881 and meet our team to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.
Join our panel discussion:
"Functional genomics for target identification: What has been achieved, what are the current challenges and what are the future opportunities "
Tuesday 6th February | 8:30am-10am | Room: 104B.
This panel discussion focuses on the vital role of functional genomics in early drug discovery, especially on the use of both pooled and arrayed CRISPR knockout screens. It will cover the need for predictive models in target identification, challenges in different fields like oncology and neuroscience, and the trade-offs in using different cell models for CRISPR screening. The panel will also debate new techniques to improve CRISPR screening outcomes and innovative strategies beyond traditional loss-of-function approaches to identify effective targets for disease research and drug discovery.
Chair
Timothy Smith, PhD - Associate Director of Sales - Americas at bit.bio
Panellists
- Davide Gianni, PhD - Senior Director Functional Genomics, Discovery Sciences, BioPharmaceuticals R&D at AstraZeneca
- Rob Howes, PhD - Head of Discovery Sciences UK at Charles River Laboratories
- Josh Tycko, PhD - Research Fellow in Neurobiology at Harvard Medical School
- Ann Byrne, PhD - Functional Genomics, Business Development Manager at bit.bio
We are also presenting the following posters:
- CRISPR knockout screening for drug target identification and validation using CRISPR-Ready ioMicroglia
Presented by Ann Byrne | Functional Genomics, Business Development Manager | bit.bio
Poster Assignment Number: 1142-C
Session: Poster Session C
Date: Tuesday February 6, 2024
Presentation Time: 12:00 PM – 1:00 PM
Track: Assay Development and Screening - CRISPR-Ready ioGlutamatergic Neurons: a functional genomics tool to easily generate disease-specific models for drug discovery and development
Presented by Ann Byrne | Functional Genomic, Business Development Manager | bit.bio
Poster Assignment Number: 1143-D
Session: Poster Session D
Date: Tuesday February 6, 2024
Presentation Time: 2:00 PM – 3:00 PM
Track: Cellular Technologies - Generation and characterisation of a panel of human iPSC-derived neurons and microglia carrying early and late onset relevant mutations for Alzheimer’s disease
Presented by Timothy Smith |Associate Director of Sales - North America | bit.bio
Poster Assignment Number: 1185-B
Session: Poster Session B
Date: Monday February 5, 2024
Presentation Time: 2:00 PM – 3:00 PM
Track: Assay Development and Screening - Rapid and consistent generation of functional motor neurons from reprogrammed human iPSCs using opti-ox technology
Presented by Timothy Smith |Associate Director of Sales - North America | bit.bio
Poster Assignment Number: 1186-C
Session: Poster Session C
Date: Tuesday February 6, 2024
Presentation Time: 12:00 PM - 1:00 PM
Track: Cellular Technologies